Genes2Me has launched a wide range of next-generation sequencing (NGS)-based panels for oncology, personalised medicine and hereditary diseases. By selectively targeting the clinically significant genes, the NGS panels from Genes2Me enable comprehensive analysis with the most effective sequencing throughput. These panels have been designed and validated for all the common NGS platforms from Illumina, Thermo Fisher ION and MGI. 

The Genes2Me PAN Cancer panel has a coverage of 525 genes. With just 50 ng of nucleic acid, the panel can detect the following biomarkers in one assay: single nucleotide variations (SNVs), insertions/deletions (INDELs), copy number variations (CNVs), microsatellite instability (MSI), fusions, splice variants and oncogenic viruses, as well as measuring the tumour mutation burden (TMB). 

The Liquid Biopsy NGS panels for colon, breast, and lung cancer are unique where superior detection sensitivity for low-frequency variants can be achieved from a limited amount of blood samples. Similarly, the NGS panels for personalised genomics allow for precise selection and dosage of prescribed drugs, and detection of genetic variants associated with drug metabolism, epilepsy and anti-tuberculosis.

Clinical Exome Sequencing (CES) Extended panel allows comprehensive genomic profiling of a variety of genetic diseases including >7,500 clinically significant genes that are not covered in any other panels, the company claimed. The other targeted panels for cardiovascular disorders, neurological conditions, bleeding disorders, metabolic disorders, dermatology, etc. will also ease the classification of these complicated conditions.

All these NGS panels are backed with automated data analysis pipelines which simplify the primary, secondary and tertiary analysis.